{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:16:20Z","timestamp":1777500980425,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,9]]},"DOI":"10.7759\/cureus.33557","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T23:11:46Z","timestamp":1673305906000},"source":"Crossref","is-referenced-by-count":6,"title":["Atezolizumab-Induced Lambert-Eaton Myasthenic Syndrome in a Patient With Small-Cell Lung Cancer"],"prefix":"10.7759","author":[{"given":"Masami","family":"Yamazoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.065","article-title":"Lambert-eaton myasthenic syndrome: diagnosis and treatment","volume":"998","author":"Sanders DB","year":"2003","unstructured":"Sanders DB. Lambert-eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci. 2003, 998:500-8. 10.1196\/annals.1254.065","journal-title":"Ann N Y Acad Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8541-9","article-title":"Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer","volume":"264","author":"Schoser B","year":"2017","unstructured":"Schoser B, Eymard B, Datt J, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol. 2017, 264:1854-63. 10.1007\/s00415-017-8541-9","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer MJ","year":"2011","unstructured":"Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011, 10:1098-107. 10.1016\/S1474-4422(11)70245-9","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-8467(02)00054-9","article-title":"Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases","volume":"104","author":"Wirtz PW","year":"2002","unstructured":"Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002, 104:359-63. 10.1016\/S0303-8467(02)00054-9","journal-title":"Clin Neurol Neurosurg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon VA","year":"1995","unstructured":"Lennon VA, Kryzer TJ, Griesmann GE, et al.. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995, 332:1467-74. 10.1056\/NEJM199506013322203","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn L","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al.. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018, 379:2220-9. 10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares L","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al.. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019, 394:1929-39. 10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini A","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, Vogrig A. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021, 96:754-66. 10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12326","article-title":"Lambert-Eaton myasthenic syndrome: clinical review","volume":"7","author":"Motomura M","year":"2016","unstructured":"Motomura M, Nakata R, Shiraishi H. Lambert-Eaton myasthenic syndrome: clinical review. Clin Exp Neuroimmunol. 2016, 7:238-45. 10.1111\/cen3.12326","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5133","article-title":"Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome","volume":"26","author":"Titulaer MJ","year":"2008","unstructured":"Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008, 26:4276-81. 10.1200\/JCO.2008.17.5133","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao JC","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, et al.. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017, 74:1216-22. 10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.40.10.1552","article-title":"Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma","volume":"40","author":"Chalk CH","year":"1990","unstructured":"Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990, 40:1552-6. 10.1212\/wnl.40.10.1552","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy\u2014review of the literature and future outlook","volume":"8","author":"M\u00f6hn N","year":"2019","unstructured":"M\u00f6hn N, Beutel G, Gutzmer R, Ivanyi P, Satzger I, Skripuletz T. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy\u2014review of the literature and future outlook. J Clin Med. 2019, 8:10.3390\/jcm8111777","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5353202","article-title":"Lambert-Eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with small-cell lung cancer","volume":"2019","author":"Agrawal K","year":"2019","unstructured":"Agrawal K, Agrawal N. Lambert-Eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with small-cell lung cancer. Case Rep Neurol Med. 2019, 2019:5353202. 10.1155\/2019\/5353202","journal-title":"Case Rep Neurol Med"},{"key":"ref15","article-title":"Immunotherapy related myasthenia gravis and Lambert Eaton syndrome case reports and review of literature","volume":"3","author":"Krishnan GS","year":"2020","unstructured":"Krishnan GS, Wilson WA. Immunotherapy related myasthenia gravis and Lambert Eaton syndrome case reports and review of literature. J immuno Immunothe. 2020, 3:007.","journal-title":"J immuno Immunothe"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.21926\/obm.neurobiol.2101086","article-title":"Case report of Lambert Eaton myasthenic syndrome in a patient with small cell lung cancer on immune checkpoint inhibitor therapy","volume":"5","author":"Anderson CJ","year":"2021","unstructured":"Anderson CJ, Guidon AC, Khan FB, Thomas AA, Riehle C, Hehir MK, Kolb NA. Case report of Lambert Eaton myasthenic syndrome in a patient with small cell lung cancer on immune checkpoint inhibitor therapy. OBM Neurobiol. 2021, 5:9. 10.21926\/obm.neurobiol.2101086","journal-title":"OBM Neurobiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8387-21","article-title":"Lambert-Eaton myasthenic syndrome caused by atezolizumab in a patient with small-cell lung cancer","volume":"61","author":"Kunii E","year":"2022","unstructured":"Kunii E, Owaki S, Yamada K, et al.. Lambert-Eaton myasthenic syndrome caused by atezolizumab in a patient with small-cell lung cancer. Intern Med. 2022, 61:1739-42. 10.2169\/internalmedicine.8387-21","journal-title":"Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27141","article-title":"Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor","volume":"63","author":"Gill AJ","year":"2021","unstructured":"Gill AJ, Gandhy S, Lancaster E. Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor. Muscle Nerve. 2021, 63:E18-21. 10.1002\/mus.27141","journal-title":"Muscle Nerve"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000494078","article-title":"Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer","volume":"10","author":"Nakatani Y","year":"2018","unstructured":"Nakatani Y, Tanaka N, Enami T, Minami S, Okazaki T, Komuta K. Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol. 2018, 10:346-52. 10.1159\/000494078","journal-title":"Case Rep Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2022.2073162","article-title":"Lambert-Eaton myasthenic syndrome (LEMS) in a patient with lung cancer under treatment with pembrolizumab: a case study","author":"Lee JH","year":"2022","unstructured":"Lee JH, Baek SK, Han JJ, Kim HJ, Lee YA, Yoo D, Maeng CH. Lambert-Eaton myasthenic syndrome (LEMS) in a patient with lung cancer under treatment with pembrolizumab: a case study. J Chemother. 2022, 1-6. 10.1080\/1120009X.2022.2073162","journal-title":"J Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131552-atezolizumab-induced-lambert-eaton-myasthenic-syndrome-in-a-patient-with-small-cell-lung-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:55Z","timestamp":1707508495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131552-atezolizumab-induced-lambert-eaton-myasthenic-syndrome-in-a-patient-with-small-cell-lung-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.33557","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,9]]}}}